TRIL

Across TCGA pan-cancer cohorts, TRIL mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRIL data layer compared with 31 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TRIL mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRIL expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

GBM, LUAD, and LSCC are the cancer types where TRIL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.899	0.709	.010	10	view →
LUAD	DFS	Median	All	1.000	0.845	.026	7	view →
LSCC	DFS	Median	III,IV	1.000	0.733	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TRIL–GBM (DFS)

Open the GBM breakdown →